Jasper Therapeutics shares surge 24.41% premarket on positive ETESIAN study data for Briquilimab in asthma and BEACON study investigation resolution.

Jasper Therapeutics, Inc. surged 24.41% in premarket trading following the release of positive preliminary data from its ETESIAN Phase 1b/2a study of Briquilimab in asthma, demonstrating significant reductions in airway hyperresponsiveness and eosinophilic response after a single 180mg dose. The results, showing improved FEV1 metrics and favorable safety profile, reinforced the drug’s potential as a novel treatment for mast cell-driven asthma. Additionally, the company concluded an internal investigation into the BEACON study’s lack of response in U.S. patients, attributing it to incorrect patient selection rather than drug product issues. These developments, coupled with an upcoming investor webinar to discuss findings, fueled optimism about Briquilimab’s therapeutic promise and regulatory pathway, driving the sharp premarket gain.